Wonderful adds $170 million secondary to $550 million round as revenue races toward $100 million

Conifers: “The attacker can walk away, and that’s what we’re least ready for”

Teva moves closer to a drug for celiac disease with positive Phase 2 results

Upwind raises $300 million, more than doubles valuation to $3.8 billion in five months